Abstracts
Breast cancer, metastatic
299P - The prevalence of PIK3CA mutations in HR+/HER2– metastatic breast cancer (BELLE2, BELLE3 and BOLERO2 clinical trials)

https://doi.org/10.1093/annonc/mdy272.289Get rights and content
Under an Elsevier user license
open archive

Cited by (0)